Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using oral finasteride for 15 years and is considering switching to a finasteride/minoxidil spray due to concerns about potential side effects like depression. They are seeking advice on whether to continue with both treatments or switch exclusively to the spray.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

Nicotine may negatively affect hair by reducing blood flow due to its vasoconstrictor properties, but its impact might be minimal. Finasteride users are advised to avoid nicotine to prevent potential hair loss issues.

A user who has been using Pyrilutamide for 5 months with no results, and other users suggesting they switch to RU58841 or stick to their treatment plan for at least one year.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.

The user is seeking alternatives to Minoxidil due to heart issues and is considering microneedling with topical melatonin, copper peptides, resveratrol+fisetin, or stemoxydine, which reportedly have minimal side effects. They are asking for information on the effectiveness of these treatments.

The user has been taking 1mg of finasteride every other day for two months, experiencing improved hair quality but disrupted sleep. They are seeking advice on whether the sleep issues will improve with continued use or if they should stop the medication.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.

The user is considering stopping topical minoxidil due to lack of improvement in hair growth and is exploring alternatives like oral minoxidil, topical finasteride, and tretinoin. They are hesitant about oral finasteride and dutasteride, and are open to trying oral minoxidil if available, despite concerns about potential heart-related side effects.

A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.

Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.

A 21-year-old is concerned about androgenic alopecia and has been using minoxidil for a year, noticing some stabilization in the hairline but fears using it on the whole scalp due to seborrheic dermatitis. Another person suggests considering a psychiatrist for stress management, using Nizoral shampoo, and possibly trying a small dose of finasteride.

The conversation is about a person using minoxidil, finasteride, estrogen, and bicalutamide to combat hair loss, expressing frustration and desperation over their situation. They are advised against using female hormones and encouraged to focus on finasteride and minoxidil, with suggestions to seek therapy for mental health support.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

Minoxidil increases blood supply to the scalp, strengthening dormant follicles and extending the growth phase, but may increase scalp activity that can be countered with DHT blockers. Women experiencing side effects from finasteride or dutasteride for hair loss might consider alternatives like estrogen, especially if on birth control.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user is concerned about whether previous use of anti-androgens like fluridil, which caused side effects, will affect future use of finasteride. They have used finasteride briefly in the past and are considering using it again.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The user is using minoxidil, topical finasteride, Nizoral shampoo, and a dermaroller for hair regrowth but is experiencing changes in sexual function. They are concerned about whether these changes are due to the treatment and are seeking advice on continuing hair growth without affecting sexuality.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Sildenafil (Viagra) shows potential for hair growth by enhancing dermal papilla cell proliferation and stimulating perifollicular vessel formation. Users discuss the possibility of using Cialis (tadalafil) similarly, noting its benefits and side effects.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.